Rep. Buddy Carter

R

Georgia – District 1

Leadership

Chairman Health

119th Congress

News & Announcements


Jun 18, 2025
Health

Chairman Guthrie Requests More Information on Improperly Shared User Data by California’s Health Insurance Marketplace Website

WASHINGTON, D.C. – Congressman Brett Guthrie (KY-02), Chairman of the House Committee on Energy and Commerce, along with Reps. Palmer (AL-06), Carter (GA-01), Bilirakis (FL-12), and Obernolte (CA-23), penned a letter to the Executive Director of Covered California (CoveredCA), Jessica Altman, to request further information related to the potentially unauthorized transmission of sensitive personal health information involving Covered California’s website. Key Letter Excerpt: “According to public reports and agency statements, tracking technology was embedded on Covered California's website beginning in February 2024, as part of a broader digital advertising effort, and in direct contravention of the tracking platform’s user agreement, which prohibits the use of such tools on pages that collect sensitive health information. Although the tags were reportedly removed in April 2025, following external scrutiny and a vendor transition, the extended period of data exposure raises serious questions about the adequacy of safeguards that Covered California had in place. Forensic testing by investigative reporters identified the trackers in operation and confirmed that user-entered health information was being transmitted to third parties without consent. These circumstances warrant examination of Covered California’s actions under federal privacy standards.” “Ensuring the confidentiality of health information is a foundational obligation for entities operating within the health insurance ecosystem. Federal privacy protections, particularly the Health Insurance Portability and Accountability Act (HIPAA), establish expectations for how covered organizations handle sensitive data. Recent reports and public filings raised questions about whether those expectations were met in this case, and whether existing oversight mechanisms are sufficient to detect and prevent improper disclosures.” Background: Forensic testing shows Covered California —the State of California’s official health insurance marketplace—has been sending sensitive user health data to third-party websites through several online data trackers. Prior to removal of the trackers, CoveredCA had more than 60 trackers active on its website; the average number of trackers on a government website is three. Some types of information sent to such websites include: Searches for doctors in network with specific plans/specializations Demographic information, including gender, ethnicity, and martial status Length of treatment a patent received by a provider Frequency of doctor visits If the user indicated they were blind, pregnant, a victim of domestic abuse, or used prescription medications. The State of California independently operates CoveredCA. As the state’s official ACA marketplace, CoveredCA falls under the purview of Health Insurance Portability and Accountability Act (HIPAA). The disclosure of information such as pregnancy or prescription drug use without proper consent—even for “marketing purposes”—may violate HIPAA. This Congress, the Committee has sent letters to 23andMe and DeepSeek over potential data privacy concerns: The Committee also held a hearing last Congress on the Change Healthcare hack, where personal health information was also jeopardized. CLICK HERE to read Fox News coverage of the letter. CLICK HERE to view the full letter. ###



Jun 17, 2025
Health

Chairmen Guthrie and Carter Announce Hearing on Department of Health and Human Services FY2026 Budget

WASHINGTON, D.C. – Today, Congressman Brett Guthrie (KY-02), Chairman of the House Committee on Energy and Commerce, and Congressman Buddy Carter (GA-01), Chairman of the Subcommittee on Health, announced a hearing titled The Fiscal Year 2026 Department of Health and Human Services Budget . “The recent passage of the OBBBA was an incredible example of how we are strengthening, securing, and sustaining our government health programs under President Trump,” said Chairmen Guthrie and Carter. “ Next week’s hearing gives us the opportunity to examine ways in which we can further incorporate health innovation, expand access to affordable care, and make America healthy again.” Subcommittee on Health hearing titled The Fiscal Year 2026 Department of Health and Human Services Budget WHAT: Subcommittee on Health hearing on Department of Health and Human Services FY26 Budget. DATE: Tuesday, June 24, 2025 TIME: 10:00 AM ET LOCATION: 2123 Rayburn House Office Building This notice is at the direction of the Chairman. The hearing will be open to the public and press and will be livestreamed online at energycommerce.house.gov . If you have any questions concerning this hearing, please contact Annabelle Huffman at Annabelle.Huffman@mail.house.gov . If you have any press-related questions, please contact Katie West at Katie.West@mail.house.gov . ###



Jun 11, 2025
Press Release

Chairman Carter Delivers Opening Statement at Subcommittee on Health Hearing on Strengthening Domestic Manufacturing and Our Health Care Supply Chain

WASHINGTON, D.C.  – Congressman Buddy Carter (GA-01), Chairman of the Subcommittee on Health, delivered the following opening statement at today’s hearing titled  Made In America: Strengthening Domestic Manufacturing And The Health Care Supply Chain. Subcommittee Chairman Carter's opening statement as prepared for delivery: “Today’s hearing is critical in addressing our nation’s reliance on adversarial countries for essential medications and health care products. This dependence not only jeopardizes our national security and patient safety, but also highlights the urgent need to increase domestic and friend-shored manufacturing. “Let me be clear: the United States should never be dependent on the Chinese Communist Party for the antibiotics and essential medicines. But that’s exactly the dangerous position we are in today. “In 2002, the United States manufactured 72 percent of the pharmaceuticals it consumed. By 2023, that number had dropped to just 37.5 percent. We didn’t just outsource manufacturing—we outsourced the sovereignty and safety of our health care system. “We saw the impacts of this reliance firsthand during the COVID-19 pandemic. According to a conversation I had with the Administration for Strategic Preparedness and Response, or ASPR, under the Trump Administration, the United States saw a downtick in the amount of PPE and pharmaceuticals coming to our country from China in the fall of 2019. We didn’t learn about COVID-19 until January 2020. “China knew there was an unidentified sickness in its own country, concealed it, and then withheld medical supplies so the United States was less prepared when COVID-19 hit our shores. “As both a pharmacist and a member of Congress, I know how critical these medicines and supplies are — especially for our national security. Under the Biden-Harris Administration, over 323 drugs were in shortage during the first quarter of 2024 – an all-time high – and cancer patients were often forced to switch treatments, adjust dosage regimens, or, in extreme cases, unable to receive their lifesaving medications. There was no comprehensive effort to support American manufacturers or reduce our reliance on foreign supply chains. “That is unacceptable. “Thankfully, President Trump is taking meaningful action by demanding real investment in our domestic production base and putting an end to decades of failed “America Last” policies that left our supply chains hollowed out and put our patients, constituents, and families at risk. “Under the leadership of President Trump, we are bringing manufacturing back to America. Since the start of this year – the start of President Trump’s second term – Johnson & Johnson broke ground on a new $2 billion facility in North Carolina, Amgen announced a $900 million manufacturing expansion in Ohio, AbbVie committed $10 billion to invest in the United States, and Sanofi announced plans to invest at least $20 billion.  “And these are just a few examples. This is just the start.  “I look forward to hearing from my other colleagues about the recent investments in their Districts and States during this hearing today, and I am thrilled to see what additional investments continue to flow and thrive under an Administration focused on unleashing innovation and bringing capacities back home.  “Along those lines, I commend recent efforts by this Administration to bolster domestic production, but we must do our part in Congress as well. This hearing will make it clear that more can be done to eliminate burdensome regulatory barriers, streamline processes that impede our competitiveness on the global stage, and establish the proper incentives to ensure we are creating the environment to allow innovation to flourish.  “It is no coincidence that Georgia – the No. 1 state in the nation to do business – is home to Manus Bio, who has invested nearly $60 million and created over 100 jobs with the acquisition of a new manufacturing facility in Augusta. We need more policies at the federal level that mirror the pro-growth examples we have in the state of Georgia.  “That is why House Republicans passed the One Big Beautiful Bill Act, which incentivizes domestic medical supply production by rewarding companies that build their products in America, like USAntibiotics, who is the last remaining end-to-end domestic U.S. manufacturer of amoxicillin, the most prescribed antibiotic in the country.  This is about protecting American lives, empowering American workers, restoring American sovereignty, and reinforcing U.S. leadership in medical innovation. “China is not our friend. Every product component that then turns into a vial of medicine or a piece of medical equipment that is made in China is a missed opportunity to strengthen our economy and protect our people. “It is time to act. We need to view pharmaceutical and health care supply chain independence just as we are viewing energy independence. I am proud to stand with President Trump and all those committed to putting America First in our health care system—starting with the medicines we rely on every day.” ###


Letters


Dec 19, 2024
Press Release

E&C Republicans Request HHS Watchdog Investigate Promotion of Gender Transition Procedures for Children

Washington, D.C. — In a new letter to Department of Health and Human Services (HHS) Inspector General Christi Grimm, House Energy and Commerce Committee Republicans requested an investigation into the strength, quality, and types of evidence-based scientific and pediatric medical literature relied on by the department to promote gender transition procedures for children.  KEY LETTER EXCERPT:  “As the agency responsible for safeguarding the health and well-being of Americans, all of HHS’s medical treatment recommendations, especially medical treatment recommendations for children, should be based on rigorous and well-established research, such as randomized controlled trials, that have definitively illustrated the long-term benefits of gender affirming care treatments.”  BACKGROUND:  Under the Biden administration, HHS has advocated for sex reassignment procedures on minors, including the use of serum puberty blockers, which have historically been used to treat children with precocious puberty (i.e., early onset puberty affecting about one percent of U.S. children) and sex offenders.   Puberty blockers, however, are known to stunt normal childhood development in children unaffected by precocious puberty.  HHS officials contend that sex reassignment procedures on minors are an unanimously accepted medical practice.  HHS Secretary Becerra testified before Congress that “every major medical association,” “medical journals,” and “scientific and medical evidence” has demonstrated the benefits of transitioning children’s biological sex.  When asked, via a Freedom of Information Act request, for the underlying scientific or medical basis for its position, HHS was only able to produce a two-page brochure that was already publicly available.  In contrast to HHS, a growing body of literature from medical experts and authorities around the world, including those in Europe, caution against performing such procedures on minors.   Courts and government health agencies responsible for determining child welfare have sought to limit child sex reassignment procedures.   Other countries have banned these interventions and surgeries on minors altogether.  An article published in the British Journal of Medicine found “there is great uncertainty about the effects of puberty blockers, cross-sex hormones, and surgeries in young people.”   A court in the United Kingdom noted the obvious about administering puberty blocking chemicals onto children: “[i]t is highly unlikely that a child aged 13 or under would be competent to give consent to the administration of puberty blockers. It is doubtful that a child aged 14 or 15 could understand and weigh the long-term risks and consequences of the administration of puberty blockers.”  In April 2024, the Cass Review , an independent review of gender identity services for children and young people, commissioned by the National Health Service England, found “[w]hile a considerable amount of research has been published in this field, systematic evidence reviews demonstrated the poor quality of the published studies, meaning there is not a reliable evidence base upon which to make clinical decisions, or for children and their families to make informed choices.”   The Cass Review also found that “[t]he rationale for early puberty suppression remains unclear, with weak evidence regarding the impact on gender dysphoria, mental or psychosocial health,” as well as unknown effects on cognitive and psychosexual development.  In August 2024, the American Society of Plastic Surgeons (ASPS) became the first major U.S. medical association to express caution on the use of gender surgery for gender dysphoria in adolescents. In its formal statement, the association stated: “ASPS currently understands that there is considerable uncertainty as to the long-term efficacy for the use of chest and genital surgical interventions for the treatment of adolescents with gender dysphoria, and the existing evidence base is viewed as low quality/low certainty. This patient population requires specific considerations.”   The letter was signed by Committee Chair Cathy McMorris Rodgers (R-WA), Subcommittee on Health Chair Brett Guthrie (R-KY), Subcommittee on Oversight and Investigations Chair Morgan Griffith (R-VA), Rep. Dan Crenshaw (R-TX), Rep. Gus Bilirakis (R-FL), Rep. Buddy Carter (R-GA), Rep. Gary Palmer (R-AL), Rep. Neal Dunn (R-FL), Rep. Randy Weber (R-TX), Rep. Troy Balderson (R-OH), Rep. August Pfluger (R-TX), Rep. Diana Harshbarger (R-TN), and Rep. Kat Cammack (R-FL).  CLICK HERE to read the letter.



Oct 7, 2024
Letter

Chair Rodgers Leads House GOP in Demanding Answers Over FCC Fast-Tracking Democrat Mega-Donor’s Media Takeover Weeks Before Election

Soros-linked fund to acquire more than 200 local radio stations weeks before election Washington, D.C. — House Energy and Commerce Committee Chair Cathy McMorris Rodgers (R-WA) led 40 of her Republican colleagues in demanding answers from the Chairwoman of the Federal Communications Commission (FCC) regarding her recent decision to fast-track a media deal allowing the Fund for Policy Reform, a group aligned with Democratic mega-donor George Soros, to buy over 200 radio stations just weeks before the 2024 election. With a party line vote of 3-2, the decision at the Commission level by the Democratic members of the FCC to temporarily waive the required national security review and allow excessive foreign ownership of American radio stations is deeply disturbing. KEY LETTER EXCERPT: “It is highly concerning that the FCC did not follow regular order for a transaction of this magnitude. Licensees and investors need certainty that the FCC will follow its rules and procedures when approving transactions so that the broadcast industry can have the resources it needs to continue serving the public.”  BACKGROUND: Audacy, Inc., a radio broadcasting group, which owns more than 200 radio-station licenses, filed for bankruptcy earlier this year.  Audacy’s filings revealed that a George Soros-backed group known as the Fund for Policy Reform had acquired at least 40 percent of Audacy’s debt.   Audacy estimated that, upon emerging from bankruptcy, 25 percent or more of its stock would be indirectly foreign owned, which triggers FCC review.   This review process requires national security agencies to review the transaction and offer any policy or national security concerns.   On September 30, 2024, the FCC released an Order granting a temporary waiver of this review process, delaying a national security review until after the bankruptcy process is complete and allowing foreign control of a significant number of radio stations across the entire United States, weeks before a national election. CLICK HERE to read Breitbart's exclusive coverage. CLICK HERE to read the full letter.



Aug 19, 2024
Press Release

E&C Republicans Expand Oversight of EPA’s $27 Billion Green Bank

Washington, D.C. — In a new letter to the Environmental Protection Agency (EPA), Energy and Commerce Committee Republicans are pressing for answers regarding Greenhouse Gas Reduction Fund (GGRF) awards. The letter to Administrator Regan, signed by Committee Chair Cathy McMorris Rodgers (R-WA), Subcommittee on Oversight and Investigations Chair Morgan Griffith (R-VA), and Subcommittee on Environment, Manufacturing, and Critical Materials Chair Earl L. "Buddy" Carter (R-GA), requests an unredacted copy of all GGRF award agreements that have been finalized.  It follows up on an Oversight Subcommittee hearing from earlier this year, where Mr. Zealan Hoover, Senior Advisor to the Administrator, assured Committee Members that the award agreements that EPA entered into with recipients to receive GGRF program awards would address the concerns raised.   LETTER TEXT BELOW:   Dear Administrator Regan,  We write to you as part of the Energy and Commerce Committee’s (the Committee) continued oversight of the Environmental Protection Agency’s (EPA) Greenhouse Gas Reduction Fund (GGRF). As you know, Committee Members have many questions regarding this first-of-its-kind, $27 billion program, including those discussed at a January 30, 2024, Subcommittee on Oversight and Investigations hearing on the GGRF, with Mr. Zealan Hoover, Senior Advisor to the Administrator, testifying on behalf of the EPA. In numerous instances, Mr. Hoover assured Members that the award agreements that EPA would enter into with recipients that the EPA selected to receive GGRF program awards would address the concerns they raised.   For example, in response to a question from Committee Chair Rodgers about what conflicts of interest policies would govern funding recipients responsible for further distributing this money, Mr. Hoover responded that “they will be subject to all of the terms and conditions of their financial assistance agreement.” After Representative Guthrie pressed for more information on whether organizations with foreign ties could receive GGRF funding, Mr. Hoover stated that “one of the terms and conditions in each of the award agreements is going to be a prohibition against entering into any form of contractual relationship with a foreign entity of concern.” Mr. Hoover also replied to Representative Lesko, “[e]ach grantee is applying with a rigorous investment plan, proposed project pipeline, and timeline for a wide array of necessary activities covering their investment work, their governance, their organizational structure. All of that will be enshrined in our terms and conditions of the grant agreement.”   Members also submitted follow-up questions for the record after the hearing. Oversight and Investigations Subcommittee Chair Griffith requested more detail about performance audits, and the EPA responded, in part, “[w]e expect that the terms and conditions of GGRF grants, as provided in 2 C.F.R. § 200.208, will authorize the project officer to closely monitor recipient performance and compliance with grant requirements.” Additionally, in response to Chair Griffith’s inquiry on how the EPA could evaluate the past performance of applicants that included new organizations or coalitions, the EPA stated that it required applicants to submit risk management plans, and that awardees would have to comply with specific terms and conditions in their award agreements. In response to a question on Build America, Buy America Act (BABA) compliance, the EPA stated that it was “including terms and conditions in the award agreements to reinforce that all grants are subject to [BABA] by statute,” and that “EPA will hold selected applicants accountable to BABA requirements through the terms and conditions of the award agreements.” Finally, the EPA also responded to a question from Representative Crenshaw, saying that “EPA will include a term and condition in all award agreements to protect against federal funds flowing to entities with certain connections to the People’s Republic of China.”  In short, the EPA repeatedly sought to reassure the Committee that its award agreements with selected recipients would address the issues of concern and potential risks. The Committee seeks additional detail on how these award agreements will address the issues of concern and potential risks.    As such, please provide a complete and unredacted copy of the award agreement, including all of the attachments, appendices, and any amendments, that the EPA executes with each funding recipient under the GGRF. By no later than August 29, 2024, please provide a copy of all award agreements that have been finalized as of the date of this letter, and please provide a copy of all remaining agreements as soon as they are finalized.